While antibodies such as rituximab have proven very efficacious for the treatment of leukaemia the clinical impact of drugs such as cetuximab (anti-EGFR) and bevacizumab (anti- VEGF) in solid tumors has, however, been less dramatic. Here, VEGFA is linked to leukemia.